 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...345678910111213...2223» |
- || Trial completion date, IO biomarker: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 6, 2023
P2, N=1460, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Dec 2022 --> Dec 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial initiation date, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Feb 2, 2023
P2, N=30, Not yet recruiting, Sponsor: Australia New Zealand Gynaecological Oncology Group
Trial completion date: Dec 2022 --> Dec 2023 Initiation date: Dec 2022 --> Mar 2023
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Jan 20, 2023
P2, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Dec 2022 --> Mar 2023 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- || ipatasertib (RG7440) / Roche
Trial primary completion date, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jan 10, 2023
P2a, N=54, Active, not recruiting, Sponsor: MedSIR
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Trial primary completion date: Nov 2022 --> Nov 2023
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
New P2 trial: Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - Jan 9, 2023
P2, N=90, Recruiting, Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
- || Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment open: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Jan 9, 2023
P2, N=30, Recruiting, Sponsor: Criterium, Inc.
Trial primary completion date: Nov 2022 --> Nov 2023 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 29, 2022
P1/2, N=30, Active, not recruiting, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Jun 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Dec 22, 2022
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Jun 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
Trial completion: A Phase I Study of SHEN26 Capsule in Healthy Participants (clinicaltrials.gov) - Dec 16, 2022
P1, N=86, Completed, Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial primary completion date: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Dec 15, 2022
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
Recruiting --> Completed Trial primary completion date: Jan 2023 --> Jan 2022
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment closed, Trial primary completion date: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Dec 8, 2022
P3, N=331, Active, not recruiting, Sponsor: Everest Medicines
Trial primary completion date: Jan 2023 --> Jan 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2023
- ||||| Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
Enrollment closed: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov) - Dec 2, 2022
P3, N=725, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- || ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Nov 29, 2022
P2a, N=54, Active, not recruiting, Sponsor: MedSIR
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion: Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer (clinicaltrials.gov) - Nov 23, 2022
P2, N=80, Completed, Sponsor: Hunan Cancer Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Margenza (margetuximab-cmkb) / MacroGenics
Trial completion: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Nov 23, 2022
P3, N=624, Completed, Sponsor: MacroGenics
Recruiting --> Completed Active, not recruiting --> Completed
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P2 trial: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 18, 2022
P2, N=63, Not yet recruiting, Sponsor: Fujian Medical University
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
New P2 trial, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Nov 17, 2022
P2, N=30, Not yet recruiting, Sponsor: Australia New Zealand Gynaecological Oncology Group
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
Kexing Biopharm's SHEN26 takes 5' mono-isobutyric este form (Twitter) - Nov 14, 2022
- ||| Enrollment closed, Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Nov 14, 2022
P1/2, N=280, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> May 2024
- | bintrafusp alfa (M7824) / EMD Serono, Halaven (eribulin mesylate) / Eisai
Trial termination, Metastases: M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 31, 2022
P1, N=38, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> May 2024 Completed --> Terminated; Due to the fact that the sponsor decided not to move forward with the development of M7824
- | bintrafusp alfa (M7824) / EMD Serono, Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Metastases: M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 28, 2022
P1, N=38, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Due to the fact that the sponsor decided not to move forward with the development of M7824 Recruiting --> Completed | N=20 --> 38
- | Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Trial initiation date: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Oct 27, 2022
P2, N=30, Not yet recruiting, Sponsor: Criterium, Inc.
Recruiting --> Completed | N=20 --> 38 Initiation date: Aug 2022 --> Nov 2022
- |||| evexomostat (SDX-7320) / SynDevRx, Halaven (eribulin mesylate) / Eisai
New P2 trial: ARETHA: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer (clinicaltrials.gov) - Oct 6, 2022
P2, N=55, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | bintrafusp alfa (M7824) / EMD Serono, Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 26, 2022
P1, N=20, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Aug 2022 --> Nov 2022 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | lobaplatin (D19466) / AEterna Zentaris, Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - Sep 19, 2022
P2, N=40, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - Sep 14, 2022
P1/2, N=41, Recruiting, Sponsor: Colette Shen
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: Feb 2026 --> Sep 2026 | Trial primary completion date: Feb 2023 --> Nov 2023
- | Ontruzant (trastuzumab-dttb) / Samsung, AffaMed Therap, Mundipharma, Organon, Halaven (eribulin mesylate) / Eisai
New P2 trial: ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 7, 2022
P2, N=180, Recruiting, Sponsor: Seoul National University Hospital
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Sep 2, 2022
P1, N=390, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2026 --> Sep 2026 | Trial primary completion date: Feb 2023 --> Nov 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
Enrollment open: A Phase I Study of SHEN26 Capsule in Healthy Participants (clinicaltrials.gov) - Aug 29, 2022
P1, N=78, Recruiting, Sponsor: Kexing Biopharm Co., Ltd.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
New P1 trial: A Phase I Study of SHEN26 Capsule in Healthy Participants (clinicaltrials.gov) - Aug 17, 2022
P1, N=78, Not yet recruiting, Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Combination therapy: Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer (clinicaltrials.gov) - Aug 4, 2022
P1/2, N=98, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Unknown status --> Completed | N=150 --> 98
- |||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jul 28, 2022
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Unknown status --> Completed | N=150 --> 98 Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024
- | Halaven (eribulin mesylate) / Eisai, Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: DETECT-IVa: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (clinicaltrials.gov) - Jul 28, 2022
P2, N=116, Active, not recruiting, Sponsor: Prof. W. Janni
Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024 Recruiting --> Active, not recruiting | N=300 --> 116 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2024
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 25, 2022
P3, N=436, Active, not recruiting, Sponsor: Byondis B.V.
Recruiting --> Active, not recruiting | N=300 --> 116 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2024 Trial completion date: May 2022 --> Oct 2022
- || Trial completion date, Trial initiation date, Trial primary completion date: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Jul 14, 2022
P2, N=131, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: May 2022 --> Oct 2022 Trial completion date: Mar 2025 --> Mar 2026 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2025 --> Mar 2026
- || Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
New P2 trial: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Jul 14, 2022
P2, N=30, Not yet recruiting, Sponsor: Criterium, Inc.
- || Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Jul 14, 2022
P1, N=19, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Mar 2025 --> Mar 2026 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2025 --> Mar 2026 Active, not recruiting --> Completed
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion: IRENE: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (clinicaltrials.gov) - Jul 13, 2022
P=N/A, N=353, Completed, Sponsor: Eisai GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Jul 12, 2022
P2, N=22, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: May 2022 --> Dec 2022
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 5, 2022
P1/2, N=30, Active, not recruiting, Sponsor: National Taiwan University Hospital
Trial primary completion date: May 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Dec 2022
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: AIRE: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (clinicaltrials.gov) - Jun 30, 2022
P4, N=82, Recruiting, Sponsor: Institut fuer Frauengesundheit
Trial completion date: Jun 2022 --> Dec 2022 Trial primary completion date: Mar 2022 --> Jan 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jun 16, 2022
P2, N=37, Completed, Sponsor: Yonsei University
Trial primary completion date: Mar 2022 --> Jan 2023 Trial completion date: Nov 2022 --> May 2022 | Trial primary completion date: Nov 2022 --> May 2022 | Active, not recruiting --> Completed
- | TSL1502 / Tasly
New P2 trial: TSL-CM-TSL1502-?: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov) - Jun 14, 2022
P2, N=125, Not yet recruiting, Sponsor: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 9, 2022
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2022 --> May 2022 | Trial primary completion date: Nov 2022 --> May 2022 | Active, not recruiting --> Completed Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, IO biomarker: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 2, 2022
P2, N=30, Recruiting, Sponsor: Beijing 302 Hospital
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jun 1, 2022
P2, N=37, Active, not recruiting, Sponsor: Yonsei University
Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023 Completed --> Active, not recruiting | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - May 31, 2022
P2, N=37, Completed, Sponsor: Yonsei University
Completed --> Active, not recruiting | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022 Active, not recruiting --> Completed
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - May 25, 2022
P2, N=57, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2022 --> Aug 2023
- |||||| Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
Enrollment open: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov) - May 24, 2022
P3, N=600, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting
- |||||||||| Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
New P3 trial: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov) - May 15, 2022
P3, N=600, Not yet recruiting, Sponsor: AstraZeneca